Dr. Arinao Ndadza

Arinao Ndadza is a pharmacogenomics researcher whose work centers on precision medicine in African populations, with a strong emphasis on warfarin dose variability. Affiliated with research networks in Southern Africa and collaborating internationally, Ndadza has contributed to advancing understanding of African ancestry–specific genetic variants influencing anticoagulant response, helping address long-standing gaps in global pharmacogenetics.

The publication record highlights genome-wide association studies and clinical pharmacogenomic profiling that identify key variants in CYP2C, VKORC1, and related loci, as well as novel signals relevant to African cohorts. This work supports development of population-tailored dosing algorithms and underscores the importance of inclusive research. An expert review further positions Ndadza as a voice in shaping future pharmacogenetics priorities across the continent.

Additional contributions include integrative genomics research in childhood obesity and participation in infectious disease surveillance studies, reflecting interdisciplinary strength. Overall, the scholarship demonstrates expertise in translating genomic discovery into clinically meaningful strategies for safer, more effective therapeutics in underrepresented populations.